Business Context and Reporting Period
Company: enGene Holdings Inc. (trading as Engene Therapeutics Inc., Symbol: ENGN)
Filing Type: Form 8-K (Current Report)
Report Date: December 22, 2025
Reporting Period: The filing announces financial results for the fiscal year ended October 31, 2025. The company is an emerging growth company incorporated in British Columbia, Canada.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific figures within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific numerical comparisons or material changes versus the prior comparable period. It only confirms the announcement of the full-year results for the period ended October 31, 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the company announced its financial results on December 22, 2025, via a press release attached as Exhibit 99.1. No specific guidance, outlook, or risk factors are detailed in the provided text.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated December 22, 2025) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the fiscal year ended October 31, 2025, including any operational milestones or clinical trial updates mentioned in the press release.
- Check the company's liquidity status and cash runway, as these are critical for a biotechnology firm and are not listed in the 8-K cover page.
- Confirm any forward-looking statements or guidance provided in the full press release.